Stock Events

Mendus AB 

€0.02
0
+€0+0% Today

Statistics

Day High
0.02
Day Low
0.02
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
Next
-0.19
0.14
0.47
0.81
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1YG.F. It's not an investment recommendation.

About

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Dr. Erik Manting Ph.D.
Employees
34
Country
SE
ISIN
SE0005003654
WKN
000A1W59F

Listings